Aldeyra Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Mar 7, 2024 and accepted by EDGAR at Mar 7, 2024, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2023-01-01 to 2023-12-31 | $29.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | −$42.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $2.1m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$37.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$0.64 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$0.64 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 58,943,205 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$30.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2023-12-31 | $147.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $148.3m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $22.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $28.5m | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $0 | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-12-31 | $15.1m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-12-31 | $119.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-027933. Last ingested by Listed: Oct 24, 2026, 15:11 ET. Listed shows no prices and gives no investment advice.